Home » Authors » Kim Coghill

Articles by Kim Coghill

CV Therapeutics, FDA Agree To Cancel Ranexa Panel Meeting

Aug. 5, 2003

ActivBiotics Raises $26.4M In Series B Round For Trials

Aug. 5, 2003

Actelion, Celltech Receive FDA Approval For Zavesca

Aug. 4, 2003

Actelion Ltd. and partner Celltech Group plc received FDA clearance to market Zavesca to Type I Gaucher's disease patients who are not candidates for Cerezyme, an orphan product made by Genzyme Corp.(BioWorld Today)

Actelion, Celltech Receive FDA Approval For Zavesca

Aug. 4, 2003

Actelion Ltd. and partner Celltech Group plc received FDA clearance to market Zavesca to Type I Gaucher's disease patients who are not candidates for Cerezyme, an orphan product made by Genzyme Corp.(BioWorld Today)

Critical Therapeutics Getting $12.5M In MedImmune Deal

Aug. 1, 2003

Pozen Submits NDA For MT 100; Rat Study Results To Be Added

Aug. 1, 2003

Critical Therapeutics Getting $12.5M In MedImmune Deal

Aug. 1, 2003

Pozen Submits NDA For MT 100; Rat Study Results To Be Added

Aug. 1, 2003

If Passed, BIOFIX Would Fix Broken Tax Code For Biotechs

July 31, 2003

If Passed, BIOFIX Would Fix Broken Tax Code For Biotechs

July 31, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...